ESCAPE-NEXT Trial
ESCAPE-NEXT is a multicentre, randomized, double-blinded, placebo-controlled, parallel Group, singledose trial designed to determine the efficacy and safety of nerinetide in participants with acute ischemic stroke undergoing endovascular thrombectomy excluding thrombolysis.
ESCAPE-NEXT is a custom designed Electronic Data Capture (EDC), Randomization and Drug Management (RDM) Interactive Resposive Technology (IRT) developed for the purpose of facilitating the data collection for the ESCAPE-NEXT Trial, while providing the following functions:
- Enables randomization of subjects based on a minimal sufficient balance algorithm
- Provides the ability to record and store patient profiles
- Provides drug management capabilities across multiple sites/locations
- Provides functionality for validating the randomization of subjects
- Provides an API integration with the IBM EDC solution
- Provides a finance module for generating invoices based on patient enrollment and follow-up visits during the trial
- Dashboards, charts and reports
- Secure & Scalable
Want to know more about DCTMS? Please visit our DCTMS Product page or contact us for a free demo!
Other links:
Ready to enroll?Get started today!
Our main areas of expertise are in the Healthcare, Academic, Education as well as the Energy Sector, where we provide solutions for a number of needs:
- - Clinical Trial Management Solutions (CTMS)
- - Interactive Response Technologies (IRT)
- - Randomization & Drug Management
- - Document Management & eTMF
- - eConsent
- - EHR Integrations
- - Custom Application Development
- - Business Intelligence & Data Integration